What's Happening?
Kye Pharmaceuticals, a Canadian specialty pharmaceutical company, has announced the availability of Dyanavel XR, an extended-release amphetamine tablet, for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Canada. The medication is approved
for use in adults and children aged 6 to 12 years. Dyanavel XR utilizes LiquiXR technology, which combines immediate and extended-release drug particles, allowing for a significant onset of action within 60 minutes and a duration of 13 hours. This development is part of Kye's commitment to expanding ADHD treatment options in Canada, aligning with the Canadian ADHD Resource Alliance's clinical practice guidelines.
Why It's Important?
The introduction of Dyanavel XR in Canada is significant as it provides healthcare professionals with an additional evidence-based treatment option for managing ADHD, a chronic neurodevelopmental disorder affecting a substantial portion of the population. The availability of a long-acting medication that can be chewed or swallowed whole without losing effectiveness is particularly beneficial for patients who require sustained symptom control throughout the day. This can improve daily functioning and quality of life for individuals with ADHD, supporting their ability to manage attention regulation and executive functioning challenges.
